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ATP-binding cassette (ABC) transporters are involved in chemotherapy resistance.
Multidrug-resistance protein 8 (ABCC11/MRP8) is also involved in 5-fluorouracil (5-FU)
metabolism. 5-FU and its derivatives are widely used in the treatment of gastrointestinal
tract cancers, but little is known about the contribution of ABCC11/MRP8 to gastrointestinal
tract and related cancers. Here, we report our investigation of ABCC11/MRP8 expression
in normal and cancerous gastrointestinal tract tissues and reveal its novel role in the
gastric mucosa. In tissue microarray and surgically resected cancer specimens,
immunohistochemical (IHC) staining revealed significantly reduced expression of ABCC11/
MRP8 in gastrointestinal tract cancers compared with other cancers. In contrast, strong
ABCC11/MRP8 expression was observed in normal gastric mucosa. Additional immuno-
fluorescence assays revealed co-localization of ABCC11/MRP8 and pepsinogen I in normal
gastric chief cells. Quantitative PCR and Western blot analysis also revealed significant
expression of ABCC11/MRP8 in fundic mucosa where the chief cells are mainly located.
Furthermore, the ABCC11 mRNA-suppressed NCI-N87 gastric cancer cell line failed to
secret pepsinogen I extracellularly. Thus, low expression of ABCC11/MRP8 is consistent
with chemotherapeutic regimens using 5-FU and its derivatives in gastrointestinal tract
cancers. Our results indicated a novel function of ABCC11/MRP8 in the regulation of
pepsinogen I secretion in the normal gastric chief cells.
Key words: ABCC11/MRP8, ABC transporter, pepsinogen I, gastric chief cells,
gastrointestinal tract
I. Introduction
The ATP-binding cassette (ABC) genes represent the
largest family of transmembrane proteins. These proteins
bind ATP and use the energy to drive the transport of vari-
ous molecules across all cell membranes [6]. Until today,
48 ABC transporters have been identified in humans [8, 22,
28]. Among those, ABC transporters, sub-family C, mem-
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ber 11, coding multidrug-resistance protein 8 (ABCC11/
MRP8) was first cloned from a cDNA library derived from
normal human breast and liver [8, 22, 28]. It contains two
conserved nucleotide-binding domains and 12 putative
transmembrane domains classified as “full transporters”
[22].
ABC transporters confer drug resistance against a
broad range of chemotherapeutic agents [8]. ABCC11/
MRP8 has been shown to act as a metabolic apparatus
of 5‑fluorouracil (5-FU) [14], which is widely used in
cancer chemotherapy [16]. 5-FU and its derivatives are
metabolized to 5-fluoro-2'-deoxyuridine 5'-monophosphate
(FdUMP) by intracellular metabolic enzymes [16, 24, 25].
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FdUMP is actively transported by ABCC11/MRP8, which
has been suggested to be involved in conferring resistance
to 5-FU [4, 5, 7, 31, 36]. In gastrointestinal tract cancers, 5-
FU-based drugs are ordinarily selected for first-line chemo-
therapy, and these drugs are known to improve both overall
and disease-free survival [25, 32].
On the other hand, ABCC11/MRP8 has specific roles
in secretory organs. Our previous studies demonstrated that
ABCC11/MRP8 was responsible for earwax secretion [27,
35]. In summary, a SNP (538G>A, Gly180Arg) in the
ABCC11 gene determines the type of earwax, and the GG
homozygous and GA heterozygous genotypes correspond
to wet earwax [35]. Similarly, ABCC11 wild type is
responsible for the secretion of pre-odoriferous compounds
from the axillary apocrine gland [27], and associated with
axillary osmidrosis [11, 21, 30]. In addition, ABCC11/
MRP8 plays a role in colostrum secretion by acting as an
efflux pump and is a peripheral factor independent of endo-
crine control [20]. These findings and the reported variety
of transport molecules associated with ABCC11/MRP8
suggest that it may also have some effect on other secretory
organs.
ABCC11/MRP8 is expressed in normal tissues includ-
ing the brain, breasts, lungs, liver, kidney, placenta, pros-
tate, testes, and apocrine glands, as well as in cancerous
tissues [3, 4, 34]. However, the contribution of ABCC11/
MRP8 to gastrointestinal tract and related cancers remains
poorly understood. The main purpose of this study was to
clarify the expression profile of ABCC11/MRP8 and its
possible function in gastrointestinal tract and related can-
cers.
II. Materials and Methods
Patients and tissue samples
Tissue samples were obtained with informed consent
from 87 patients treated surgically at Nagasaki University
Hospital (Table 1). Formalin-fixed paraffin-embedded
(FFPE) sections were subjected to immunohistochemical
(IHC) staining and immunofluorescence (IF) assay. Fresh
frozen samples of normal gastric mucosa were also
obtained from gastric cancer patients. A tissue microarray
(Human Multiple Normal and Cancer Tissue Array, Protein
Biotechnologies, Ramona, CA, USA) containing 48 normal
tissues and 48 solid cancers was also used to analyze
ABCC11/MRP8 expression.
Cell lines and related chemicals
Human gastric cancer cell line NCI-N87 (CRL 5822)
was obtained from the American Type Culture Collection
(ATCC, Manassas, VA, USA). Human gastric cancer cell
line HGC-27 (RCB 0500), which did not have the morpho-
logical and enzyme-histochemical characteristics of glan-
dular epithelial cells [1], was provided by RIKEN BRC
through the National Bio-Resource Project of the MEXT,
Japan. These cell lines were characterized and authen-
ticated at the repository by methods such as mycoplasma
infection testing and DNA identification testing (short
tandem repeat analysis) and were used within 6 months of
purchase. The cells were maintained in RPMI 1640 (Life
Technologies, Carlsbad, CA, USA) supplemented with
10% (v/v) heat-inactivated fetal bovine serum (Life
Technologies) and 1% (v/w) penicillin/streptomycin (Life
Technologies). Cells were subcultured using 0.05%
trypsin-0.53 mM EDTA solution (Life Technologies). For
the ABCC11 mRNA suppression assay, cells were cultured
in Opti-MEM I serum-free medium (Life Technologies).
Antibodies
For IHC staining, primary antibodies were used at the
following concentrations: rabbit polyclonal anti-human
ABCC11/MRP8 antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), 1:200 and mouse monoclonal
anti‑human pepsinogen I antibody (Sanbio BV, Uden, The
Netherlands), 1:500. Horseradish peroxidase (HRP)-
conjugated goat polyclonal anti-rabbit IgG (Nichirei Bio-
sciences, Tokyo, Japan) and HRP-conjugated goat poly‐
clonal anti-mouse IgG (Nichirei Biosciences) were used as
Table 1. Characteristics of patients and ABCC11/MRP8 IHC staining scores
n (male, female) Mean Age (range) IHC Staining Score
Breast Cancer 14 (0, 14) 61.9 (49–88) 1.75±0.51***
HCC/CCC 10 (10, 0) 67.2 (53–76) 1.65±0.88**
Pancreatic Cancer 5 (2, 3) 67.6 (52–81) 1.00±0.35*
Lung Cancer 19 (14, 5) 65.1 (42–79) 1.05±0.69**
Thyroid Cancer 5 (2, 3) 51.4 (24–76) 0.80±0.76
Gastrointestinal tract Cancer 34 (17, 17) 64.1 (43–88) 0.44±0.54
 Esophageal 5 (3, 2) 65.4 (63–69) 0.70±0.57
 Gastric 16 (6, 10) 61.7 (37–79) 0.25±0.45
 Colorectal 13 (8, 5) 66.7 (43–82) 0.54±0.59
Total 87 (45, 42) 63.8 (24–88) 1.00±0.80
n, number of patients analyzed; HCC, hepatocellular carcinoma; CCC, cholangiocellular carcinoma. IHC
Staining score was calculated by two investigators using clarification criteria as described. Data represent
mean values±SD. */ **/ ***; significant difference between gastrointestinal tract cancer and cancers of other
organs, P<0.05 (*), P<0.01 (**), and P<0.001 (***), based on a nonparametric Mann–Whitney U test.
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detecting antibodies. Alexa Fluor 488-conjugated goat poly-
clonal anti-rabbit IgG (Life Technologies), 1:2000 and
Alexa Fluor 594-conjugated goat polyclonal anti-mouse
IgG (Life Technologies), 1:2000 were also used as
detecting antibodies in the IF assay. In the Western blot
analysis, additional mouse monoclonal anti-actin antibody
(Abcam, Cambridge, MA, USA) or anti-GAPDH antibody
were used as internal controls.
Immunohistochemical staining and immunofluorescence
assay
FFPE sections were deparaffinized in dimethylben-
zene and rehydrated through a graded alcohol series. After
antigen retrieval in HistoVT One (Nacalai Tesque, Kyoto,
Japan) (95°C, 20 min), blocking of endogenous peroxidase
activity in 3% H2O2 solution, sections were incubated with
each primary antibody (4°C, overnight). After washing in
PBS, sections were incubated with the detecting antibody
(room temperature, one hour). For IHC staining, sections
were visualized with 3,3'-diaminobenzidine tetra hydro-
chloride (DAB: brown) or 3-amino-9-ethylcarbazole (AEC:
red) and counterstained with hematoxylin. The sections
visualized with DAB were dehydrated with alcohol and
dimethylbenzene and mounted in a conventional fashion.
Sections visualized with AEC were mounted in aqueous
media without dehydration. Normal breast tissue speci-
mens, which moderately expressed ABCC11/MRP8 [4]
were prepared as positive controls in all cases. Negative
controls were also prepared in all cases by substituting the
primary antibody. The IHC staining scores were calculated
by two investigators using the following criteria: score 0,
no expression; score 1, low expression <10%; score 2,
moderate expression >10% or diffuse staining; score 3,
strong expression >90%, or strong focal staining. The mean
values were determined for each cancer.
For IF assay, sections were mounted in mounting
media with 4',6-diamidino-2-phenylindole (DAPI). Double
IF assays were observed by confocal laser scanning
microscopy (LSM 510 META, Carl Zeiss, Oberkochen,
Germany) or fluorescence microscopy (BX70, Olympus,
Tokyo, Japan).
ELISA
The amount of pepsinogen I secreted in culture
medium was measured by specific ELISA tests (Biohit Plc,
Helsinki, Finland). All experiments were performed in
duplicate. The mean values of each sample were normal-
ized by the concentration of the total protein.
Western blot analysis
To extract whole proteins, the gastric mucosa speci-
mens were homogenized in radio-immunoprecipitation
assay (RIPA) buffer (Nacalai Tesque) using a Bioruptor
(Tosho Denki, Yokohama, Japan). Following centrifugation
at 5,000 g for 10 min, the supernatant fraction was col-
lected. For culture samples, the supernatant fraction of
each culture medium was collected. Whole cell lysates
were prepared as cytoplasmic fractions using RIPA buffer
(Nacalai Tesque). The protein concentrations of all samples
were quantified using a BCA Protein Assay Kit (Thermo
Fisher Scientific, Waltham, MA, USA). The same amount
of protein from each sample was prepared in a sample buf-
fer (ATTO, Tokyo, Japan) containing SDS. The proteins
were then separated by 8% SDS-PAGE (Tefco, Tokyo,
Japan) and electro-transferred to polyvinylidene difluoride
(PVDF) membranes (GE Healthcare, Buckinghamshire,
UK). One hour after blocking in Tris-buffered saline con-
taining 0.1% (v/v) Tween 20 (TBS-T) and 1% (w/v) skim
milk, primary and detecting antibodies were used at their
own concentrations. HRP-dependent luminescence was
developed using ECL Plus Western Blotting Detecting
Reagents (GE Healthcare), and was detected with a Lumino
Imaging Analyzer FluorChem Imaging System (Cell Bio-
sciences, Santa Clara, CA, USA) according to the manufac-
turer’s specifications.
Total RNA extraction and quantitative PCR
Total RNA was extracted using High Pure RNA
Isolation Kit (Roche Diagnostics, Mannheim, Germany).
Reverse transcription was performed with 2 μg of the
total RNA using High-Capacity Reverse Transcription
(Life Technologies). Quantitative PCR analysis was per-
formed using a Life Technologies Prism 7900HT Sequence
Detection System. TaqMan probes and primers for
ABCC11/MRP8 were obtained as assay-on-demand gene
expression products (assay ID: Hs01090768_m1, Life
Technologies). The mRNA of pepsinogen I was analyzed
using the following primer set (sense primer, 5'-CCC
GTC TTT GAC AAC ATC TG-3'; anti-sense primer, 5'-
CGC TGC CAC TCT TGT CAT C-3'). The mRNA of
GAPDH was used as an endogenous control (assay ID:
Hs99999905_m1, Life Technologies). The thermal cycler
conditions were as follows: held for 10 min at 95°C fol-
lowed by two-step PCR for 45 cycles of 95°C for 15 sec
and 60°C for 1 min. All experiments were performed in
quadruplicate. The number of transcripts was calculated
from a standard curve obtained by plotting the known input
of six different concentrations versus the PCR cycle num-
ber at which the detected fluorescence intensity reached a
fixed value. Amplification data were analyzed with Prism
Sequence Detection Software version 2.1 (Life Technolo-
gies). For each sample, data were normalized to GAPDH.
ABCC11 mRNA suppression by RNA interference
Cells were suspended in serum-free Opti-MEM I
medium (Life Technologies) at a concentration of 105 cells/
well. Small interfering RNA (siRNA) for ABCC11 (pre-
designed siRNA, ID: s39907) and negative-control siRNA
(Silencer negative control siRNA, ID: AM4611) were
purchased from Life Technologies. Prepared cells were
transfected with siRNA according to the manufacturer’s
specifications using 5 μl siPORT NeoFX Transfection
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agent (Life Technologies) to produce a final RNA concen-
tration of 50 nmol/l in serum-free medium. The cells were
harvested after two days of transfection. The efficiency
of siRNA transfection was determined by quantitative
PCR, and WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-
nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium mono-
sodium salt] [12] (Nacalai Tesque) assay was also
performed to determine cell viability.
Statistical analysis
Statistical significance was assessed using either
unpaired Student’s t-test for parametric data or Mann–
Whitney U test for nonparametric data. StatView software
version 5.0 (SAS Institute, Cary, NC, USA) was used for
all statistical analyses.
III. Results
ABCC11/MRP8 expression in solid cancers
Representative positive- and negative-stained cancer
specimens obtained from cancer patients are shown in Fig-
ure 1. Genetically, the expression of ABCC11/MRP8 was
proved in normal tissues of liver and breast by PCR [3, 34].
In our experiments, almost all specimens of HCC and
breast cancer were ABCC11/MRP8 positive, and they were
observed in the cytoplasm (Fig. 1a and b). In contrast,
almost all specimens of gastric cancer and colon cancer
were negative (Fig. 1c and d).
Representative positive- and negative-stained cancer
specimens in the tissue microarray (48 normal tissues and
48 cancers) are shown in Figure 2A. ABCC11/MRP8
expression in 87 cancer patients was analyzed using the
IHC Staining Score based on the classification criteria. In
gastrointestinal tract cancers, ABCC11/MRP8 expression
was significantly lower than that in breast, HCC/CCC, pan-
creatic, and lung cancers (Fig. 2B).
Localization of ABCC11/MRP8 in normal stomach
ABCC11/MRP8 expression was observed in the
normal gastric mucosa. In low magnification images,
ABCC11/MRP8 immunopositive cells are gathered in the
fundic glands similarly to pepsinogen I (Fig. 3A). In high
magnification images, positive cells contained vacuolar
structures in the cytoplasm, and the nuclei were pushed
aside, suggesting that these were gastric chief cells (Fig.
3B). In contrast, larger, round gastric parietal cells were not
stained with ABCC11/MRP8 and pepsinogen I.
To clarify the co-localization of ABCC11/MRP8 with
pepsinogen I, double immunofluorescent (IF) assay was
performed. In double IF assay of the normal gastric
mucosa, ABCC11/MRP8-and pepsinogen I-expressing
cells were completely matched (Fig. 4A and B). Pepsin-
Representative positive- and negative-stained cancer specimens obtained from cancer patients. a, HCC (moderately differentiated); b, breast can-
cer (invasive ductal carcinoma); c, gastric cancer (moderately differentiated adenocarcinoma); d, colon cancer (well differentiated adenocarcinoma).
Upper specimens are ABCC11/MRP8 positive and lower specimens are negative.
Fig. 1. 
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producing NCI-N87 cells [2, 20] were also immunopositive
for ABCC11/MRP8 and pepsinogen I, co-localizing in the
cytoplasm (Fig. 4C).
Quantitative PCR assay revealed significant expres-
sion of ABCC11/MRP8 in gastric fundic mucosa
(P<0.005), which overlapped the distribution of gastric fun-
dic glands (Fig. 5A). Western blot analysis of ABCC11/
MRP8 also showed limited localization in fundic mucosa
(Fig. 5B).
Alteration of pepsinogen I secretion by ABCC11 siRNA
transfection
NCI-N87 cells secret pepsin and they have been used
as a model of human gastric epithelial functions [2, 20]. To
investigate the contribution of pepsinogen I secretion by
ABCC11 mRNA expression, NCI-N87 cells were used in
an ABCC11 mRNA suppression assay with siRNA. Figure
6A shows almost 80% reduction in ABCC11 expression in
NCI-N87 cells transfected with ABCC11 siRNA compared
with control cells. ELISA assay showed that the ABCC11
reduced by siRNA almost abolished pepsinogen I secretion
to the extracellular culture medium without decreasing
cell viability (P<0.005 vs. negative siRNA) (Fig. 6B and
C). Although the cells transfected with ABCC11 siRNA
failed to secrete pepsinogen I extracellularly, cytoplasmic
pepsinogen I mRNA and pepsinogen I were not altered
(Fig. 6D and E).
IV. Discussion
In the present study, we investigated the expression of
ABCC11/MRP8 in various cancers and revealed that this
expression was reduced in gastrointestinal tract cancers
compared with breast, HCC/CCC, pancreatic, and lung
cancers. ABCC11/MRP8 has been reported to contribute
to multidrug-resistance especially 5-FU and its derivatives
[24, 31, 36]. Our finding of reduced ABCC11/MRP8 ex-
pression in gastrointestinal tract cancers supports the view
A: Representative ABCC11/MRP8 staining of the tissue microarray. a and b, lung cancer (adenocarcinoma); c and d, breast cancer (infiltrating
ductal carcinoma); e and f, colon cancer (mucinous adenocarcinoma); g, gastric cancer (mucinous adenocarcinoma). Upper specimens are ABCC11/
MRP8 positive and lower specimens are ABCC11/MRP8 negative. Note that all gastric cancers are ABCC11/MRP8 negative. Bar=200 μm. B:
ABCC11/MRP8 IHC Staining Scores for 87 surgically resected sections. HCC, hepatocellular carcinoma; and CCC, cholangiocellular carcinoma. Dot
plots are representative of each IHC Staining Score, and horizontal bars represent the mean values. Statistical significance between cancer types was
determined by a nonparametric Mann–Whitney U test. *, P<0.05; **, P<0.01; and ***, P<0.001.
Fig. 2. 
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that these cancers are sensitive to 5-FU and its derivatives,
and this is consistent with findings from routine chemother-
apy regimens [16]. The investigation of expression level of
ABCC11/MRP8 may provide us with useful information
for making choices when tailor-making chemotherapies as
well as for evaluating histoculture drug response assay or
collagen gel droplet embedded culture drug sensitivity
test. Hlavata and colleagues analyzed the relations
between transcript levels of all known ABC transporters
in colorectal cancers and chemotherapy efficiency, and
revealed that ABCC11/MRP8 might be a promising
candidate marker for 5-FU therapy [10]. Furthermore,
Uemura and colleagues demonstrated that ABCC11/MRP8
directly confers resistance to pemetrexed, a new-generation
antifolate antimetabolite [31]. In gastrointestinal tract
cancers, chemotherapies with pemetrexed are currently
under investigation. Our findings might add further insight
on the potential clinical benefits of pemetrexed in gastro-
intestinal tract cancers.
In the present study, the over-expressions of ABCC11/
MRP8 were not observed in 16 gastric cancer patients.
However, reported cell line based studies have demon-
strated that increased expression of ABCC11/MRP8
directly conferred chemoresistance [24, 31]. Considering
the colorectal cancer studies, the relations between the
expression levels of ABCC11/MRP8 and chemoresistance
to 5-FU might be observed also in gastric cancers. Addi-
tional investigations are required to elucidate the possible
role of biological effect of ABCC11/MRP8 for chemore-
sistance in gastric cancers.
We also intensively analyzed ABCC11/MRP8 expres-
sion in normal gastric mucosa because of the strong immu-
nohistochemical staining in gastric chief cells. To the best
of our knowledge, the present study is the first to reveal the
expression of ABCC11/MRP8 in normal gastric mucosa.
Interestingly, ABCC11/MRP8 expression was observed in
normal gastric mucosa. However, it was almost negative in
gastric cancers regardless of their histological types or dif-
A: Representative ABCC11/MRP8 and pepsinogen I staining images in serial sections of normal gastric mucosa obtained from three different
patients. B: ABCC11/MRP8 and pepsinogen I staining in serial sections of surgically resected normal gastric mucosa at high magnification. Black
arrowheads indicate gastric chief cells, and white arrowheads indicate gastric parietal cells.
Fig. 3. 
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ferentiations (poorly adenocarcinoma; 6, signet ring cell
carcinoma; 5, moderately adenocarcinoma; 3, others; 3).
This discrepancy may be explained by the origin of gastric
cancers. In humans, intestinal metaplasia and spasmolytic
polypeptide-expressing metaplasia (SPEM) are associated
with the precancerous stomach [33]. Nozaki and colleagues
reported that gastric chief cells transdifferentiated into
SPEM cells with down-regulated mature chief cell markers
including pepsinogen I [23].
Pepsinogen I is secreted by gastric chief cells in fundic
glands around the upper stomach. Pepsinogen II is secreted
in the pyloric and Brunner’s glands around the lower stom-
ach as well as fundic gland [9, 13]. The present study indi-
cated that ABCC11/MRP8 was expressed in the upper
portion of the gastric mucosa. Therefore, we hypothesized
that ABCC11/MRP8 regulated pepsinogen I secretion, and
not pepsinogen II. Pepsinogen synthesis and secretion are
regulated by positive and negative feedback mechanisms
[26]. In theory, pepsinogens are synthesized on the endo-
plasmic reticulum and modified at the Golgi body, then,
once stored in granules, they are secreted through an exo-
cytosis process [9, 26]. The releasing process and modu-
Double immunofluorescence assay of surgically resected normal gastric mucosa and NCI-N87 cells with the following fluorescence-labeled anti-
bodies: green, ABCC11/MRP8; red, pepsinogen I; and blue, DAPI. A: Low magnification of normal gastric mucosa, confocal laser scanning micro-
scopy. Bar=50 μm. B: High magnification of normal gastric mucosa, confocal laser scanning microscopy. Bar=10 μm. C: High magnification of NCI-
N87 cells fixed with 3.7% paraformaldehyde, fluorescence microscopy. Bar=10 μm.
Fig. 4. 
ABCC11/MRP8 in Gastrointestinal Tract 91
lators that bind the gastric chief cell receptors with specific
antagonists have been studied intensively. However, the
mechanism by which they are sequestered into granules and
moved to the plasma membrane for exocytosis has not been
identified. In the present study, ABCC11-knocked down
cells could synthesize pepsinogen I intracellularly, but
failed to secrete it extracellularly. Considering the molecu-
lar weight of the pepsinogen I, it may be too large for a
transportation substrate of ABCC11/MRP8 [36]. Thus, the
mechanism of reducing pepsinogen I with ABCC11-
knockdown might be an indirect suppression, through some
smaller molecule essential to the generating process of
pepsinogen I. Although further research is necessary for
elucidation of the mechanisms, our results suggest that
ABCC11/MRP8 might play a crucial role in the prelimi-
nary steps of pepsinogen I exocytosis.
Previously, we reported the functional modification of
ABCC11/MRP8 that determined the phenotype of earwax
by a SNP of the ABCC11 gene [35]. Similarly, ABCC11
genotype is responsible for the secretion in the axillary
apocrine gland [29], and axillary osmidrosis [11, 20, 30]. In
addition, ABCC11 genotype is also responsible for secre-
tion of colostrum [20]. Considering our experimental data
and the studies cited here, ABCC11/MRP8 might be a key
molecule of “exocrine” function in various tissues. It is
still unknown whether the SNP genotype correlates with
pepsinogen I secretion. Serum pepsinogen tests were
Localization of ABCC11/MRP8 in the normal gastric mucosa
was investigated using specimens from surgically resected patients. A:
Quantitative real-time PCR analysis of 19 specimens for four parts of
the normal gastric mucosa: upper, cardia, and fundus; middle, body of
stomach; lower, pyloric antrum and pyloric canal; and duodenum, supe-
rior part of the duodenum. The right schematic shows the definitions of
each part of the stomach. Data represent the mean±SD. Statistical sig-
nificance was determined by unpaired Student’s t-test. **, P<0.01 and
***, P<0.001. B: Western blot analysis of gastric cancer cell lines
(NCI-N87 and HGC-27) and normal gastric specimens from four parts
of the gastric mucosa. GAPDH was used as the internal control protein.
Fig. 5. 
introduced for mass screening of chronic gastritis and
gastric cancer [15, 17–19]. Therefore, it would be clinically
important to investigate the SNP genotype and pepsinogen
I. Additional studies of ABCC11/MRP8 including SNP
genotyping and secretion models might help to clarify the
mechanism of exocrine systems in the gastrointestinal tract.
In conclusion, low expression of ABCC11/MRP8 was
Alteration of pepsinogen I secretion by ABCC11 siRNA was
investigated using NCI-N87 cells. A: Quantitative real-time PCR analy-
sis of ABCC11 mRNA two days after siRNA transfection. Data were
normalized to housekeeping gene GAPDH mRNA. Graph shows the
relative ABCC11 expression compared with negative siRNA as 100%.
Data represent mean±SD. B: Secreted pepsinogen I in each culture
medium measured by ELISA two days after siRNA transfection. Graph
shows relative pepsinogen I secretion compared with negative siRNA
as 100%. Statistical significance was determined by unpaired Student’s
t-test. ***, P<0.001. C: Cell viability was evaluated by WST-8 assay to
investigate the cytotoxicity associated with the transfection agents or
manipulations at two days after transfection. Graph shows the relative
viability compared with negative siRNA as 100%. Data represent the
mean±SD. Statistical significance was determined by unpaired Stu-
dent’s t-test. n.s., not significant. D: Quantitative real-time PCR analy-
sis of pepsinogen 1 mRNA at two days after siRNA transfection. Data
were normalized to housekeeping gene GAPDH. Graph shows the rela-
tive pepsinogen 1 mRNA expression compared with negative siRNA as
100%. Data represent the mean±SD. E: Western blot analysis for pep-
sinogen I. Cytoplasmic proteins from each fraction of NCI-N87 cells
transfected with ABCC11 siRNA were extracted at two days after
transfection in triplicate. NCI-N87 cells transfected with negative
siRNA were used as a positive control, and HGC-27 cells were used as
a negative control. Actin was used as the internal control protein.
Fig. 6. 
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found in gastrointestinal tract cancers. Our findings would
have some implications for the rational understanding of
chemoresistance in gastrointestinal tract cancers. Further-
more, our findings also indicate a novel function of
ABCC11/MRP8 in normal gastric chief cells, which regu-
late pepsinogen I secretion, possibly in the process of exo-
cytosis. These results might give us a new insights into
pepsinogen production and ABCC11/MRP8 regulation in
gastric diseases.
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